Development challenges for medicines for central nervous system disorders
An analysis of over 100 applications submitted between 1995 and 2014 to the European Medicines Agency (EMA) shows that various challenges can arise in the development of medicines meant to treat central nervous system (CNS) disorders, and highlights the importance of an appropriate design of early-stage clinical trials for future success in the development.
